Interaction between endogenous bacterial flora and latent HIV infection

Clinical and Vaccine Immunology

Volumn 20, Issue 6, 2013, Pages 773-779

  Victoriano, Ann Florence B ^a   Imai, Kenichi ^a,b   Okamoto, Takashi ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b NIHON UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 DEAZANEPLANOCIN A; ANTIRETROVIRUS AGENT; BUTYRIC ACID; CD4 ANTIGEN; CHETOCIN; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 8; HISTONE H3; HISTONE H4; HISTONE METHYLTRANSFERASE; INTERLEUKIN 17; METHYLTRANSFERASE INHIBITOR; N (1 BENZYL 4 PIPERIDINYL) 2 (HEXAHYDRO 4 METHYL 1H 1,4 DIAZEPIN 1 YL) 6,7 DIMETHOXY 4 QUINAZOLINAMINE; PROSTRATIN; TAIPOXIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 4; TRICHOSTATIN A; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VALPROIC ACID; VIRUS RNA; VORINOSTAT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADAPTIVE IMMUNITY; ANAEROCOCCUS TETRADIUS; BACTERIAL FLORA; CANDIDA ALBICANS; CD4+ T LYMPHOCYTE; CHROMATIN; CLOSTRIDIUM; CLOSTRIDIUM COCHLEARIUM; COMMENSAL; CYTOKINE PRODUCTION; DRUG POTENTIATION; ESCHERICHIA COLI; FUSOBACTERIUM NUCLEATUM; GENE EXPRESSION REGULATION; GRAM NEGATIVE BACTERIUM; HISTONE ACETYLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; INTESTINE FLORA; LATENT VIRUS INFECTION; MOUTH FLORA; NONHUMAN; OPPORTUNISTIC INFECTION; ORGANISMAL INTERACTION; PORPHYROMONAS GINGIVALIS; PRIORITY JOURNAL; PROTEIN DEPLETION; RECEPTOR UPREGULATION; SHORT SURVEY; T CELL DEPLETION; TH17 CELL; VAGINA FLORA; VIRUS REACTIVATION; VIRUS REPLICATION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; BACTERIA; BACTERIAL INFECTIONS; HIV; HIV INFECTIONS; HUMANS; MICROBIAL INTERACTIONS; MICROBIOTA;

EID: 84878339262     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00766-12     Document Type: Short Survey

References (92)

1. Sandler NG, Douek DC. 2012. Microbial translocation in HIV infection: causes, consequences and treatment opportunities. Nat. Rev. Microbiol. 10:655-666.
2. Hunt PW. 2012. HIV and inflammation: mechanisms and consequences. Curr. HIV/AIDS Rep. 9:139-147.
3. Báfica A, Scanga CA, Schito M, Chaussabel D, Sher A. 2004. Influence of coinfecting pathogens on HIV expression: evidence for a role of Toll-like receptors. J. Immunol. 172:7229-7234. (Pubitemid 38747580)
4. Blanchard A, Montagnier L, Gougeon ML. 1997. Influence of microbial infections on the progression of HIV disease. Trends Microbiol. 5:326-331. (Pubitemid 27362296)
5. Kotler DP. 2005. HIV infection and the gastrointestinal tract. AIDS 19:107-117. (Pubitemid 40409529)
6. Belyakov IM, Ahlers JD. 2012. Mucosal immunity and HIV-1 infection: applications for mucosal AIDS vaccine development. Curr. Top. Microbiol. Immunol. 354:157-179.
7. Brenchley JM, Douek DC. 2008. HIV infection and the gastrointestinal immune system. Mucosal Immunol. 1:23-30.
8. Kader M, Wang X, Piatak M, Lifson J, Roederer M, Veazey R, Mattapallil JJ. 2009. Alpha4(+)beta7(hi)CD4(+) memory T cells harbor most Th-17 cells and are preferentially infected during acute SIV infection. Mucosal Immunol. 2:439-449.
9. Elhed A, Unutmaz D. 2010. Th17 cells and HIV infection. Curr. Opin. HIV AIDS 5:146-150.
10. Dandekar S, George MD, Baumler AJ. 2010. Th17 cells, HIV and the gut mucosal barrier. Curr. Opin. HIV AIDS 5:173-178.
11. Cecchinato V, Trindade CJ, Laurence A, Heraud JM, Brenchley JM, Ferrari MG, Zaffiri L, Tryniszewska E, Tsai WP, Vaccari M, Parks RW, Venzon D, Douek DC, O'Shea JJ, Franchini G. 2008. Altered balance between Th17 and Th1 cells at mucosal sites predicts AIDS progression in simian immunodeficiency virus-infected macaques. Mucosal Immunol. 1:279-288. (Pubitemid 351850534)
12. Chege D, Sheth PM, Kain T, Kim CJ, Kovacs C, Loutfy M, Halpenny R, Kandel G, Chun TW, Ostrowski M, Kaul R. 2011. Sigmoid Th17 populations, the HIV latent reservoir, and microbial translocation in men on long-term antiretroviral therapy. AIDS 25:741-749.
13. Favre D, Lederer S, Kanwar B, Ma ZM, Proll S, Kasakow Z, Mold J, Swainson L, Barbour JD, Baskin CR, Palermo R, Pandrea I, Miller CJ, Katze MG, McCune JM. 2009. Critical loss of the balance between Th17 and T regulatory cell populations in pathogenic SIV infection. PLoS Pathog. 5:e1000295. doi:10.1371/journal.ppat.1000295.
14. + T-cell restoration in gut-associated lymphoid tissue of HIV-infected patients is associated with enhanced Th17 cells and polyfunctional HIV-specific T-cell responses. Mucosal Immunol. 1:475-488.
15. Estes JD, Harris LD, Klatt NR, Tabb B, Pittaluga S, Paiardini M, Barclay GR, Smedley J, Pung R, Oliveira KM, Hirsch VM, Silvestri G, Douek DC, Miller CJ, Haase AT, Lifson J, Brenchley JM. 2010. Damaged intestinal epithelial integrity linked to microbial translocation in pathogenic simian immunodeficiency virus infections. PLoS Pathog. 6:e1001052. doi:10.1371/journal.ppat.1001052.
16. + T cells in vitro is enhanced by exposure to commensal Escherichia coli. J. Immunol. 189:885-896.
17. Ahmed N, Hayashi T, Hasegawa A, Furukawa H, Okamura N, Chida T, Masuda T, Kannagi M. 2010. Suppression of human immunodeficiency virus type 1 replication in macrophages by commensal bacteria preferentially stimulating Toll-like receptor 4. J. Gen. Virol. 91:2804-2813.
18. Cassone A, Cauda R. 2012. Candida and candidiasis in HIV-infected patients: where commensalism, opportunistic behavior and frank pathogenicity lose their borders. AIDS 26:1457-1472.
19. Imai K, Ochiai K, Okamoto T. 2009. Reactivation of latent HIV-1 infection by the periodontopathic bacterium Porphyromonas gingivalis involves histone modification. J. Immunol. 182:3688-3695.
20. Imai K, Yamada K, Tamura M, Ochiai K, Okamoto T. 2012. Reactivation of latent HIV-1 by a wide variety of butyric acid-producing bacteria. Cell. Mol. Life Sci. 69:2583-2592.
21. González OA, Li M, Ebersole JL, Huang CB. 2010. HIV-1 reactivation induced by the periodontal pathogens Fusobacterium nucleatum and Porphyromonas gingivalis involves Toll-like receptor 2 [corrected] and 9 activation in monocytes/macrophages. Clin. Vaccine Immunol. 17:1417-1427.
22. González OA, Ebersole JL, Huang CB. 2011. The oral commensal, Streptococcus gordonii, synergizes with Tat protein to induce HIV-1 promoter activation in monocytes/macrophages. Cell. Immunol. 269:38-45.
23. Giacaman RA, Asrani AC, Gebhard KH, Dietrich EA, Vacharaksa A, Ross KF, Herzberg MC. 2008. Porphyromonas gingivalis induces CCR5-dependent transfer of infectious HIV-1 from oral keratinocytes to permissive cells. Retrovirology 5:29. doi:10.1186/1742-4690-5-29.
24. Sha BE, Zariffard MR, Wang QJ, Chen HY, Bremer J, Cohen MH, Spear GT. 2005. Female genital-tract HIV load correlates inversely with Lactobacillus species but positively with bacterial vaginosis and Mycoplasma hominis. J. Infect. Dis. 191:25-32. (Pubitemid 40041396)
25. Sewankambo N, Gray RH, Wawer MJ, Paxton L, McNaim D, Wabwire-Mangen F, Serwadda D, Li C, Kiwanuka N, Hillier SL, Rabe L, Gaydos CA, Quinn TC, Konde-Lule J. 1997. HIV-1 infection associated with abnormal vaginal flora morphology and bacterial vaginosis. Lancet 350:546-550. (Pubitemid 27348430)
26. Mirmonsef P, Krass L, Landay A, Spear GT. 2012. The role of bacterial vaginosis and Trichomonas in HIV transmission across the female genital tract. Curr. HIV Res. 10:202-210.
27. Taha TE, Hoover DR, Dallabetta GA, Kumwenda NI, Mtimavalye LA, Yang LP, Liomba GN, Broadhead RL, Chiphangwi JD, Miotti PG. 1998. Bacterial vaginosis and disturbances of vaginal flora: association with increased acquisition of HIV. AIDS 12:1699-1706. (Pubitemid 28418342)
28. Al-Harthi L, Roebuck KA, Olinger GG, Landay A, Sha BE, Hashemi FB, Spear GT. 1999. Bacterial vaginosis-associated microflora isolated from the female genital tract activates HIV-1 expression. J. Acquir. Immune Defic. Syndr. 21:194-202. (Pubitemid 29331213)
29. Hashemi FB, Ghassemi M, Faro S, Aroutcheva A, Spear GT. 2000. Induction of human immunodeficiency virus type 1 expression by anaerobes associated with bacterial vaginosis. J. Infect. Dis. 181:1574-1580. (Pubitemid 30387747)
30. Spiegel CA, Amsel R, Eschenbach D, Schoenknecht F, Holmes KK. 1980. Anaerobic bacteria in nonspecific vaginitis. N. Engl. J. Med. 303:601-607. (Pubitemid 10053753)
31. Jiang W, Ghosh SK, Flyckt R, Kalinowska M, Starks D, Jurevic R, Weinberg A, Lederman MM, Rodriguez B. 2012. Bacterial colonization and beta defensins in the female genital tract in HIV infection. Curr. HIV Res. 10:504-512.
32. Siliciano RF, Greene WC. 2011. HIV latency. Cold Spring Harbor Perspect. Med. 1:a007096. doi:10.1101/cshperspect.a007096.
33. Margolis DM. 2010. Mechanisms of HIV latency: an emerging picture of complexity. Curr. HIV/AIDS Rep. 7:37-43.
34. Hakre S, Chavez L, Shirakawa K, Verdin E. 2011. Epigenetic regulation of HIV latency. Curr. Opin. HIV AIDS 6:19-24.
35. Colin L, Van Lint C. 2009. Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology 6:111. doi:10.1186/1742-4690-6-111.
36. Victoriano AF, Okamoto T. 2012. Transcriptional control of HIV replication by multiple modulators and their implication for a novel antiviral therapy. AIDS Res. Hum. Retroviruses 28:125-138.
37. Choudhary SK, Margolis DM. 2011. Curing HIV: pharmacologic approaches to target HIV-1 latency. Annu. Rev. Pharmacol. Toxicol. 51:397-418.
38. Burnett JC, Lim KI, Calafi A, Rossi JJ, Schaffer DV, Arkin AP. 2010. Combinatorial latency reactivation for HIV-1 subtypes and variants. J. Virol. 84:5958-5974.
39. Savarino A, Mai A, Norelli S, El Daker S, Valente S, Rotili D, Altucci L, Palamara AT, Garaci E. 2009. "Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence. Retrovirology 6:52. doi:10.1186/1742-4690-6-52.
40. Bouchat S, Gatot JS, Kabeya K, Cardona C, Colin L, Herbein G, De Wit S, Clumeck N, Lambotte O, Rouzioux C, Rohr O, Van Lint C. 2012. Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4(+) T cells from HIV-1-infected HAART-treated patients. AIDS 26:1473-1482.
41. Bernhard W, Barreto K, Saunders A, Dahabieh MS, Johnson P, Sadowski I. 2011. The Suv39H1 methyltransferase inhibitor chaetocin causes induction of integrated HIV-1 without producing a T cell response. FEBS Lett. 585:3549-3554.
42. Okamoto T, Akagi T, Shima H, Miwa M, Shimotohno K. 1987. Superinduction of trans-activation accounts for augmented human immunodeficiency virus replication in HTLV-I-transformed cells. Jpn. J. Cancer Res. 78:1297-1301. (Pubitemid 18038272)
43. Okamoto T, Matsuyama T, Mori S, Hamamoto Y, Kobayashi N, Yamamoto N, Josephs SF, Wong-Staal F, Shimotohno K. 1989. Augmentation of human immunodeficiency virus type 1 gene expression by tumor necrosis factor alpha. AIDS Res. Hum. Retroviruses 5:131-138. (Pubitemid 19116042)
44. Mbopi-Kéou FX, Belec L, Teo CG, Scully C, Porter SR. 2002. Synergism between HIV and other viruses in the mouth. Lancet Infect. Dis. 2:416-424. (Pubitemid 34693259)
45. Andreani G, Lodge R, Richard D, Tremblay MJ. 2012. Mechanisms of interaction between protozoan parasites and HIV. Curr. Opin. HIV AIDS 7:276-282.
46. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, Kazzaz Z, Bornstein E, Lambotte O, Altmann D, Blazar BR, Rodriguez B, Teixeira-Johnson L, Landay A, Martin JN, Hecht FM, Picker LJ, Lederman MM, Deeks SG, Douek DC. 2006. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 12:1365-1371. (Pubitemid 44924494)
47. Haynes BF. 2006. Gut microbes out of control in HIV infection. Nat. Med. 12:1351-1352. (Pubitemid 44924488)
48. Klatt NR, Funderburg NT, Brenchley JM. 2013. Microbial translocation, immune activation, and HIV disease. Trends Microbiol. 21:6-13.
49. Handley SA, Thackray LB, Zhao G, Presti R, Miller AD, Droit L, Abbink P, Maxfield LF, Kambal A, Duan E, Stanley K, Kramer J, Macri SC, Permar SR, Schmitz JE, Mansfield K, Brenchley JM, Veazey RS, Stappenbeck TS, Wang D, Barouch DH, Virgin HW. 2012. Pathogenic simian immunodeficiency virus infection is associated with expansion of the enteric virome. Cell 151:253-266.
50. Verdin E, Paras P, Jr, Van Lint C. 1993. Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. EMBO J. 12:3249-3259. (Pubitemid 23232756)
51. Jordan A, Bisgrove D, Verdin E. 2003. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J. 22:1868-1877. (Pubitemid 36460143)
52. Laughlin MA, Zeichner S, Kolson D, Alwine JC, Seshamma T, Pomerantz RJ, Gonzalez-Scarano F. 1993. Sodium butyrate treatment of cells latently infected with HIV-1 results in the expression of unspliced viral RNA. Virology 196:496-505.
53. Van Lint C, Emiliani S, Ott M, Verdin E. 1996. Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J. 15:1112-1120. (Pubitemid 26077840)
54. Grunstein M. 1997. Histone acetylation in chromatin structure and transcription. Nature 389:349-352. (Pubitemid 27415209)
55. Murphy M, Ahn J, Walker KK, Hoffman WH, Evans RM, Levine AJ, George DL. 1999. Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev. 13:2490-2501. (Pubitemid 29489641)
56. Ashburner BP, Westerheide SD, Baldwin AS, Jr. 2001. The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol. Cell. Biol. 21:7065-7077. (Pubitemid 32916079)
57. Imai K, Okamoto T. 2006. Transcriptional repression of human immunodeficiency virus type 1 by AP-4. J. Biol. Chem. 281:12495-12505. (Pubitemid 43855336)
58. Coull JJ, Romerio F, Sun JM, Volker JL, Galvin KM, Davie JR, Shi Y, Hansen U, Margolis DM. 2000. The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. J. Virol. 74:6790-6799. (Pubitemid 30470662)
59. Williams SA, Chen LF, Kwon H, Ruiz-Jarabo CM, Verdin E, Greene WC. 2006. NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J. 25:139-149. (Pubitemid 43077303)
60. Jiang G, Espeseth A, Hazuda DJ, Margolis DM. 2007. c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter. J. Virol. 81:10914-10923. (Pubitemid 47536066)
61. Tyagi M, Karn J. 2007. CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency. EMBO J. 26:4985-4995. (Pubitemid 350261291)
62. Keedy KS, Archin NM, Gates AT, Espeseth A, Hazuda DJ, Margolis DM. 2009. A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression. J. Virol. 83:4749-4756.
63. Huber K, Doyon G, Plaks J, Fyne E, Mellors JW, Sluis-Cremer N. 2011. Inhibitors of histone deacetylases: correlation between isoform specificity and reactivation of HIV type 1 (HIV-1) from latently infected cells. J. Biol. Chem. 286:22211-22218.
64. Barton K, Margolis D. 2013. Selective Targeting of the repressive transcription factors YY1 and cMyc to disrupt quiescent human immunodeficiency viruses. AIDS Res. Hum. Retroviruses 29:289-298.
65. Victoriano AF, Imai K, Togami H, Ueno T, Asamitsu K, Suzuki T, Miyata N, Ochiai K, Okamoto T. 2011. Novel histone deacetylase inhibitor NCH-51 activates latent HIV-1 gene expression. FEBS Lett. 585:1103-1111.
66. Pinskaya M, Morillon A. 2009. Histone H3 lysine 4 di-methylation: a novel mark for transcriptional fidelity? Epigenetics 4:302-306.
67. Kouzarides T. 2007. Chromatin modifications and their function. Cell 128:693-705. (Pubitemid 46273577)
68. du Chéné I, Basyuk E, Lin YL, Triboulet R, Knezevich A, Chable-Bessia C, Mettling C, Baillat V, Reynes J, Corbeau P, Bertrand E, Marcello A, Emiliani S, Kiernan R, Benkirane M. 2007. Suv39H1 and HP1gamma are responsible for chromatin-mediated HIV-1 transcriptional silencing and post-integration latency. EMBO J. 26:424-435. (Pubitemid 46160943)
69. Marban C, Suzanne S, Dequiedt F, de Walque S, Redel L, Van Lint C, Aunis D, Rohr O. 2007. Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing. EMBO J. 26:412-423. (Pubitemid 46160942)
70. Pearson R, Kim YK, Hokello J, Lassen K, Friedman J, Tyagi M, Karn J. 2008. Epigenetic silencing of human immunodeficiency virus (HIV) transcription by formation of restrictive chromatin structures at the viral long terminal repeat drives the progressive entry of HIV into latency. J. Virol. 82:12291-12303.
71. Imai K, Togami H, Okamoto T. 2010. Involvement of histone H3 lysine 9 (H3K9) methyltransferase G9a in the maintenance of HIV-1 latency and its reactivation by BIX01294. J. Biol. Chem. 285:16538-16545.
72. Easley R, Van Duyne R, Coley W, Guendel I, Dadgar S, Kehn-Hall K, Kashanchi F. 2010. Chromatin dynamics associated with HIV-1 Tatactivated transcription. Biochim. Biophys. Acta 1799:275-285.
73. Le Douce V, Colin L, Redel L, Cherrier T, Herbein G, Aunis D, Rohr O, Van Lint C, Schwartz C. 2012. LSD1 cooperates with CTIP2 to promote HIV-1 transcriptional silencing. Nucleic Acids Res. 40:1904-1915.
74. Friedman J, Cho WK, Chu CK, Keedy KS, Archin NM, Margolis DM, Karn J. 2011. Epigenetic silencing of HIV-1 by the histone H3 lysine 27 methyltransferase enhancer of Zeste 2. J. Virol. 85:9078-9089.
75. Viré E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, Morey L, Van Eynde A, Bernard D, Vanderwinden JM, Bollen M, Esteller M, Di Croce L, de Launoit Y, Fuks F. 2006. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439:871-874. (Pubitemid 43255707)
76. Tae S, Karkhanis V, Velasco K, Yaneva M, Erdjument-Bromage H, Tempst P, Sif S. 2011. Bromodomain protein 7 interacts with PRMT5 and PRC2, and is involved in transcriptional repression of their target genes. Nucleic Acids Res. 39:5424-5438.
77. Kauder SE, Bosque A, Lindqvist A, Planelles V, Verdin E. 2009. Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog. 5:e1000495. doi:10.1371/journal.ppat.1000495.
78. Blazkova J, Trejbalova K, Gondois-Rey F, Halfon P, Philibert P, Guiguen A, Verdin E, Olive D, Van Lint C, Hejnar J, Hirsch I. 2009. CpG methylation controls reactivation of HIV from latency. PLoS Pathog. 5:e1000554. doi:10.1371/journal.ppat.1000554.
79. Van Lint C, Emiliani S, Verdin E. 1996. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expression 5:245-253.
80. Moog C, Kuntz-Simon G, Caussin-Schwemling C, Obert G. 1996. Sodium valproate, an anticonvulsant drug, stimulates human immunodeficiency virus type 1 replication independently of glutathione levels. J. Gen. Virol. 77(Pt 9):1993-1999. (Pubitemid 26316066)
81. Quivy V, Adam E, Collette Y, Demonte D, Chariot A, Vanhulle C, Berkhout B, Castellano R, de Launoit Y, Burny A, Piette J, Bours V, Van Lint C. 2002. Synergistic activation of human immunodeficiency virus type 1 promoter activity by NF-kappaB and inhibitors of deacetylases: potential perspectives for the development of therapeutic strategies. J. Virol. 76:11091-11103. (Pubitemid 35176225)
82. Archin NM, Espeseth A, Parker D, Cheema M, Hazuda D, Margolis DM. 2009. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res. Hum. Retroviruses 25:207-212.
83. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, Parker DC, Anderson EM, Kearney MF, Strain MC, Richman DD, Hudgens MG, Bosch RJ, Coffin JM, Eron JJ, Hazuda DJ, Margolis DM. 2012. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487:482-485.
84. Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, Wiegand A, Landay AL, Coombs RW, Richman DD, Mellors JW, Coffin JM, Bosch RJ, Margolis DM. 2005. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 366:549-555. (Pubitemid 41140329)
85. Margolis DM. 2011. Histone deacetylase inhibitors and HIV latency. Curr. Opin. HIV AIDS 6:25-29.
86. Willemsen NM, Hitchen EM, Bodetti TJ, Apolloni A, Warrilow D, Piller SC, Harrich D. 2006. Protein methylation is required to maintain optimal HIV-1 infectivity. Retrovirology 3: 92. doi:10.1186/1742-4690-3-92.
87. + cell infection. PLoS One 5:e9390. doi:10.1371/journal.pone.0009390.
88. Sagot-Lerolle N, Lamine A, Chaix ML, Boufassa F, Aboulker JP, Costagliola D, Goujard C, Pallier C, Delfraissy JF, Lambotte O. 2008. Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. AIDS 22:1125-1129.
89. Arrieta MC, Finlay BB. 2012. The commensal microbiota drives immune homeostasis. Front. Immunol. 3:33. doi:10.3389/fimmu.2012.00033.
90. Brenchley JM, Douek DC. 2008. The mucosal barrier and immune activation in HIV pathogenesis. Curr. Opin. HIV AIDS 3:356-361. (Pubitemid 351521021)
91. + cell count. AIDS 25:1385-1394.
92. Saxena D, Li Y, Yang L, Pei Z, Poles M, Abrams WR, Malamud D. 2012. Human microbiome and HIV/AIDS. Curr. HIV/AIDS Rep. 9:44-51.